Melanoma Combo Cuts Recurrence Risk ~42% as Analysts Split on Moderna
MRNA has more than doubled off its 52-week low of $22.28.
Summary
The Phase 3 intismeran/Keytruda melanoma combo cut recurrence or death risk by about 42% and distant metastasis by about 38% across more than 1,100 patients, with two-year relapse-free survival of 82.2% versus 70%. Overall survival data are still immature. This follows the 2026-10-22 leak of the closely guarded study details, and the formal numbers now confirm the direction of that leak. Analyst reaction is split: Bernstein calls it strong validation of the individualized neoantigen platform but stays Market Perform with a $45 target, TD Cowen keeps Hold and $90, and Citi reiterates Sell, questioning whether individualized tumor harvesting and roughly six-week manufacturing are commercially justified. The stock fell below its 20-day moving average after the leak and then rebounded, with valuation and cash-flow concerns competing against the clinical win. The ESMO presentation is the next scheduled disclosure point for the full dataset.
At the time of this announcement, MRNA was trading at $201.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.9B. The 52-week trading range was $22.28 to $254.48. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.